Top Page
WORK Medical Technology Group LTD
(NASDAQ:WOK)
WORK Medical Technology Group LTD (WOK) vs. SPDR S&P 500 ETF (SPY)
WORK Medical Technology Group LTD Business Overview & Revenue Model
WORK Medical Technology Group LTD Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.74M | 11.51M | 13.57M | 19.71M | 45.86M | 52.53M |
| Gross Profit | 2.89M | 2.87M | 4.14M | 4.42M | 8.64M | 10.85M |
| EBITDA | -4.09M | -1.71M | 2.08M | 4.72M | 11.87M | 4.75M |
| Net Income | -3.71M | -3.49M | 112.03K | 865.21K | 5.96M | 1.16M |
Balance Sheet | ||||||
| Total Assets | 34.71M | 36.25M | 29.96M | 25.54M | 30.66M | 56.20M |
| Cash, Cash Equivalents and Short-Term Investments | 2.00M | 6.56M | 1.60M | 731.18K | 508.71K | 200.40K |
| Total Debt | 13.04M | 13.47M | 9.10M | 6.30M | 6.60M | 4.05M |
| Total Liabilities | 19.00M | 20.18M | 18.97M | 14.35M | 19.26M | 50.27M |
| Stockholders Equity | 12.95M | 13.19M | 9.88M | 10.00M | 10.04M | 4.90M |
Cash Flow | ||||||
| Free Cash Flow | -13.20M | -11.49M | 1.63M | -4.27M | -7.24M | 9.65M |
| Operating Cash Flow | -3.76M | -2.23M | 2.21M | -2.26M | -7.18M | 27.20M |
| Investing Cash Flow | 318.29K | -9.06M | -583.30K | -1.35M | -60.00K | -16.84M |
| Financing Cash Flow | 2.05M | 15.66M | -728.72K | 3.57M | 7.99M | -10.28M |
WORK Medical Technology Group LTD Technical Analysis
WORK Medical Technology Group LTD Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $29.79M | -1.48 | -85.01% | ― | -16.59% | 43.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $8.77M | -0.64 | -74.10% | ― | 53.22% | 72.69% | |
42 Neutral | $3.48M | >-0.01 | ― | ― | ― | 60.83% | |
41 Neutral | $179.60K | ― | ― | ― | ― | ― |
WORK Medical Technology Group LTD Corporate Events
On December 30, 2025, WORK Medical Technology Group LTD entered into a securities purchase agreement with LWY GROUP LTD, an existing shareholder wholly owned by the company’s chief operating officer, Baiming Yu, for the issuance and sale of 100,000 Class B ordinary shares at an aggregate purchase price of $500,000 under Regulation S of the U.S. Securities Act of 1933. The transaction, which was approved by the company’s audit committee and full board and is expected to close on or about January 13, 2026, will increase Yu’s beneficial holdings to 100,625 Class B shares, representing approximately 54.96% of the company’s total voting power, thereby consolidating insider control and potentially shaping future corporate governance and strategic direction for shareholders.
The most recent analyst rating on (WOK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.
On October 21, 2025, WORK Medical Technology Group LTD shareholders approved resolutions authorizing one or more consolidations of the company’s authorized, issued and outstanding ordinary shares within a range of 2:1 to 250:1, along with adopting an amended and restated memorandum of association to reflect any such changes. Following this approval, the board resolved on November 29, 2025 to implement a 100:1 share consolidation, which took effect on December 29, 2025, reducing the company’s outstanding ordinary shares from about 122.0 million to approximately 1.22 million and similarly consolidating its authorized share capital, with fractional shares rounded up and electronic holdings adjusted automatically, in order to raise the per-share price and allow the company to more quickly regain compliance with Nasdaq’s minimum bid price requirement and reduce the risk of delisting; the Class A ordinary shares continue to trade on Nasdaq under the symbol “WOK” with a new CUSIP.
The most recent analyst rating on (WOK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.
On November 20, 2025, WORK Medical Technology Group LTD announced a new sales agreement with AC Sunshine Securities, LLC, allowing the company to offer and sell Class A ordinary shares through the sales agent. The agreement enables the company to raise up to $200 million, with shares sold at the company’s discretion, reflecting a strategic move to enhance market liquidity and financial flexibility. This development could potentially impact the company’s market position and provide stakeholders with opportunities for investment.
The most recent analyst rating on (WOK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.
On November 7, 2025, WORK Medical Technology Group LTD held an Extraordinary General Meeting of Shareholders in Hangzhou, China, where key resolutions were adopted. These included a share capital increase, amendments to the company’s memorandum and articles of association, and approval of potential share consolidations. The resolutions aim to enhance the company’s financial structure and operational flexibility, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (WOK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.
WORK Medical Technology Group LTD has successfully regained compliance with the Nasdaq Minimum Bid Price Requirement as of November 4, 2025. This compliance was achieved by maintaining a minimum closing bid price of $1.00 or greater for its Class A Ordinary Shares over a consecutive 10-day period, effectively closing the matter with Nasdaq and stabilizing its market position.
The most recent analyst rating on (WOK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.
On September 12, 2025, WORK Medical Technology Group LTD held an extraordinary general meeting where shareholders approved resolutions for a share consolidation and an increase in authorized share capital to ensure compliance with Nasdaq’s minimum bid price requirement. The consolidation, effective October 21, 2025, adjusted the company’s share structure to prevent delisting risks, with shares now trading under the same symbol ‘WOK’ but with a new CUSIP number. This strategic move aims to stabilize the company’s market position and maintain its Nasdaq listing, impacting shareholders by consolidating shares at a 100:1 ratio and increasing authorized capital to $10 million.
The most recent analyst rating on (WOK) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.
WORK Medical Technology Group LTD has announced an extraordinary general meeting scheduled for November 7, 2025, to discuss significant changes to its share capital structure. The meeting will address resolutions to increase the company’s authorized share capital from $10 million to $100 million and to consolidate shares, which could impact shareholder value and market positioning. These changes follow a previous board decision on September 29, 2025, to consolidate and increase share capital, reflecting the company’s strategic efforts to enhance its financial flexibility and operational capacity.
The most recent analyst rating on (WOK) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.